NewsBenzinga리어링크 파트너스, 트위스트 바이오사이언스에 대한 ‘시장수익률 상회’ 의견 유지···목표주가 175달러로 하향 리어링크 파트너스, 트위스트 바이오사이언스에 대한 ‘시장수익률 상회’ 의견 유지···목표주가 175달러로 하향 Benzinga 2026.11.13 20:16 (GMT+0) Open on Benzinga Other news Meta Internally Tests Prediction Market App 'Takes' Leerink Partners Maintains Outperform on Twist Bioscience, Lowers Price Target to $175 Microsoft Says Infrastructure Stabilizes As Queued Messages Drain And Traffic Rebalances, With No ETA For Full Recovery JP Morgan Maintains Overweight on Sea, Lowers Price Target to $132 JP Morgan Maintains Overweight on Lithium Americas, Lowers Price Target to $5 JP Morgan Maintains Overweight on Cellebrite DI, Lowers Price Target to $15
Microsoft Says Infrastructure Stabilizes As Queued Messages Drain And Traffic Rebalances, With No ETA For Full Recovery
